Close Menu

NEW YORK (GenomeWeb) – Startup mFluiDx — a portmanteau of "microfluidics" and "diagnostics" — is developing an inexpensive, sample-to-answer, self-digitizing quantitative microfluidic diagnostics platform that does not require an external instrument to run.

The mFludiX diagnostic is able to process whole blood with on-chip sample prep and requires simple external heating and a simple optical reader, similar to a DNA gel reader, to obtain quantitative results, mFluiDx co-founder Charlie Yeh said in an interview.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.